Nasdaq · CIK 0001860657
ALLR Allarity Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 3 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at Allarity Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | Jeremy R. Graff See Remarks | MOption exercise Common Stock | +48,147 | - | - | 73,028 | 3 d ago |
| Jan 22, 2026 | Jeremy R. Graff See Remarks | FTax withholding Common Stock | -17,814 | $1.18 | $21k | 55,214 | 3 d ago |
| Sep 30, 2026 | Jeremy R. Graff See Remarks | MOption exercise Common Stock | +39,494 | - | - | 94,708 | 3 d ago |
| Sep 30, 2026 | Jeremy R. Graff See Remarks | FTax withholding Common Stock | -14,613 | $0.97 | $14k | 80,095 | 3 d ago |
| Jan 22, 2026 | Jeremy R. Graff See Remarks | MOption exercise Restricted Stock Unitsderivative | -48,147 | $0.00 | $0 | 175,283 | 3 d ago |
| Sep 30, 2026 | Jeremy R. Graff See Remarks | MOption exercise Restricted Stock Unitsderivative | -39,494 | $0.00 | $0 | 269,122 | 3 d ago |
| Jan 7, 2026 | Jeremy R. Graff See Remarks | AGrant or award Common Stock | +133,333 | $0.00 | $0 | 381,644 | Jan 16, 2026 |
| Sep 30, 2025 | Jeremy R. Graff See Remarks | MOption exercise Common Stock | +39,494 | - | - | 39,494 | Oct 2, 2025 |
| Sep 30, 2025 | Jeremy R. Graff See Remarks | FTax withholding Common Stock | -14,613 | $1.58 | $23k | 24,881 | Oct 2, 2025 |
| Sep 30, 2025 | Jeremy R. Graff See Remarks | MOption exercise Restricted Stock Unitsderivative | -39,494 | $0.00 | $0 | 223,430 | Oct 2, 2025 |
| Jan 22, 2025 | Laura Benjamin director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 24, 2025 |
| Jan 22, 2025 | Joseph Walter Vazzano director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 24, 2025 |
| Jan 22, 2025 | Gerald W. McLaughlin director | AGrant or award Stock Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 24, 2025 |
| Jan 22, 2025 | Thomas Jensen CEO | AGrant or award Common Stock | +396,734 | $0.00 | $0 | 396,734 | Jan 24, 2025 |
| Jan 22, 2025 | Alexander Epshinsky CFO | AGrant or award Common Stock | +29,496 | $0.00 | $0 | 85,051 | Jan 24, 2025 |
| Jan 22, 2025 | Jeremy R. Graff CDO | AGrant or award Common Stock | +144,441 | $0.00 | $0 | 262,924 | Jan 24, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Laura Benjamindirector
- Alexander EpshinskyCFO
- Jeremy R. GraffSee Remarks
- Thomas JensenCEO
- Gerald W. McLaughlindirector
- Joseph Walter Vazzanocfo, officer, director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.